RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, m
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent
After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a short-ter
Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicate
Here is how Adma Biologics (ADMA) and CareDx (CDNA) have performed compared to their sector so far this year.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
The ADMA Biologics (ADMA) stock surges in a month on impressive second-quarter results. It has recently hit its 52-week high with more room for growth.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Gro
Adma Biologics (ADMA) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago.
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Erie Indemnity (ERIE), TreeHouse (THS), HII (HII) and ADMA Biologics (ADMA) are well-poised to gain.
RAMSEY, N.J. and BOCA RATON, Fla.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE